IRI Separation Technologies Inc.

IRI Separation Technologies Inc.

June 23, 2008 09:00 ET

IRI Separation Technologies Inc.: Further Corporate Update

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 23, 2008) - IRI Separation Technologies Inc. (the "Company") (TSX VENTURE:IRI) Further to our June 19 announcement the Company is pleased to announce it has an arrangement with one of the largest egg producers in the world, whereby the Company is able to "borrow" egg yolks for processing at the Company's Immunoglobulin IgY extraction and purification plant in Airdrie, Alberta. This plant remains in production as stated on June 19.

The Company only temporarily closed its Airdrie egg breaking facility as it is more economical to acquire liquid yolk elsewhere as shown above for its general antibody product.

The Company is able to process far more Yolk than it was capable of producing at its own breaking plant at considerable cost savings with far less exposure to the fluctuations and supply problems associated with shell egg supply.

The Company views the temporary closure of the egg breaking facility as a very positive move, allowing its resources to be used in the Company's core business.

IRI Separations Tech Inc now is concentrating its efforts towards bringing our unique Mono Boost product to market. In this respect the Company has signed up 4200 stores across all of Canada, to market our product. The uniqueness of the product is significant as it is the first of its kind to be marketed anywhere in the world. The Company has completed the design and has built our commercials to be shown on National Television, magazines and Flyer ads.

The company brings to the market a product designed to increase the human immune system. Currently as all people age our immune systems dissipates until death occurs from a variety of causes. With a strong immune system the quality of life greatly improves as we age.

Products in our research and development pipeline include antibodies to specific disease agents (C.Deficile, Avian Flu, Acne, H.Pylori, Parvo virus (pet food), E-coli/Salmonella, Rotovirus, Candeda Albicans).

IRI Separation Technologies Inc. (TSX VENTURE:IRI) is a biotechnology company that specializes in the extraction, development and commercialization of polyclonal antibodies for virus and bacteria related health issues. Intended for use as a nutraceutical for human consumption, the antibodies are derived from chicken eggs. The antibodies are intended for both the general and specific antibody market.

Forward Looking Statements: The above contains forward looking statements that are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in our forward looking statements. Factors that could cause such differences include: changes in world markets for nutraceuticals, equity market conditions, costs and supply of materials relevant to the nutraceutical industry, change in government and changes to regulations affecting the nutraceutical industry. Forward-looking statements in this release include statements regarding future store listings, operation plans, the MUNO® product launch, and the potential financing. Although we believe the expectations reflected in our forward looking statements are reasonable, results may vary, and we cannot guarantee future results, levels of activity, performance or achievements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • IRI Separation Technologies Inc. - Investor Inquiries
    John Mason
    Chairman of the Board
    IRI Separation Technologies Inc. - Investor Relations
    Paul Frigstad
    Manager of Investor Relations
    (604) 929-7332
    1-888-822-9231 (FAX)
    IRI Separation Technologies Inc.
    Rick Stiksma
    President & CEO
    (604) 637-3152 local 522
    (604) 854-6599 (FAX)